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(B) 8 weeks of self-management plus a verum splint; or (C) 8 weeks of
self-management plus a placebo splint. The self-management pro-
gramme was designed and delivered by therapists, based on
recommended evidence-based practice. Participants in groups B
and C were blinded to the type of splint received; clinical outcome
assessors were also blinded. Participants were followed-up for 12
weeks from randomisation. The primary outcome was AUSCAN hand
pain at 8 weeks. Secondary outcomes included work productivity,
QoL, hand stiffness, hand function, disability and satisfaction. The trial
was registered (ISRCTN. No 54744256).
Results: 17 UK NHS therapy departments assessed 751 patients for
eligibility. 349 patients were randomised: 116, 116 and 117 to groups
A, B and C, respectively. Treatment groups were well balanced for
baseline characteristics. At baseline, no participants in group A
received a splint; 99% and 97% of participants in groups B and C
received the correct allocated splint. 80% of all participants attended
their 4 week follow-up appointment. 8 week primary endpoint data
were available for 84% of randomised participants; missing data were
balanced across the groups. There was no evidence of clinically or
statistically significant differences between treatment arms (B vs. C: -
0.4 (95% CI -1.4, 0.6 p¼ 0.41), B vs. A: -0.5 (95% CI -1.4, 0.4 p¼0.26),
C vs. A: -0.1 (95% CI -1.0, 0.8 p¼ 0.78). The per-protocol analysis,
sensitivity analysis for missing data and analyses of secondary
endpoints supported these findings. Ten participants reported adverse
reactions: 3, 5 and 2 in groups A, B and C, respectively.
Conclusion: The addition of splinting to the recommended self-
management package delivered by therapists did not confer additional
benefit. Patients randomised to receive verum splints did not report
better outcomes than those randomised to placebo splints.
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Background: Evidence of the effectiveness of intra-articular corticoster-
oid injection for hip osteoarthritis (OA) is limited. The HIT trial compared
the clinical and cost-effectiveness of an ultrasound-guided intra-articular
hip injection (USGI) of 40mg triamcinolone acetonide and 4ml 1%
lidocaine hydrochloride combined with best current treatment (BCT) with
(i) BCT alone (primary objective) and (ii) an USGI of 5ml 1% lidocaine only
combined with BCT (EudraCT:2014-003412-37).
Methods: This was a pragmatic, three-parallel arm, single-blind,
randomised controlled trial in adults with moderate-severe painful hip
OA recruited from community musculoskeletal services and primary
care. Participants were randomised equally to: (1) BCT alone, (2) BCT
plus USGI triamcinolone/lidocaine, or (3) BCT plus USGI lidocaine
only. Outcomes were collected postally at 2 weeks, 2, 4 and 6 months.
The primary outcome was self-reported current hip pain intensity (0-10
numeric rating scale (NRS)) over 6 months (repeated measures
analysis). Secondary outcomes included function (WOMAC), and, for
cost-utility analysis, general health (EQ-5D-5L) and healthcare utilisa-
tion. 204 participants were required to detect a minimum difference of
1 point in mean pain NRS score between arms (1) and (2) with 80%
power (5% two-tailed significance level, 15% loss to follow-up).
Analysis was by intention-to-treat.
Results: 199 participants were recruited (43% male, mean age 63
years), 67 to arm (1) and 66 each to arms (2) and (3). Primary outcome
completion rates were 95% at 2 weeks, 94% at 2 months, 90% at 4
months, and 89% at 6 months. Greater mean improvement in hip pain
intensity (0-10 NRS) over 6 months was seen with BCT plus USGI
triamcinolone/lidocaine compared with BCT alone: -1.43 (95%CI -
2.15,-0.72). Greater mean improvement in pain intensity was seen at 2
weeks (-3.17; -4.06,-2.28) and 2 months (-1.81;-2.71,-0.92), but not at
4 (-0.86;-1.78,0.05) or 6 months (0.12; -0.80,1.04). Participants treated
with BCT plus USGI triamcinolone/lidocaine compared with BCT alone
had greater mean improvement in function (WOMAC-F -5.47;(-9.41,-
1.53)) over 6 months. There was no statistically significant difference in
hip pain intensity over 6 months between BCT plus USGI
triamcinolone/lidocaine compared with BCT plus USGI lidocaine (-
0.52;-1.21,0.18). There was one possible treatment-related serious
adverse event: a participant with no signs of infection at randomisation
died from endocarditis four months after USGI triamcinolone/lido-
caine. BCT plus USGI triamcinolone/lidocaine was less costly (mean
cost difference per participant £-161.59) and associated with
significantly higher quality-adjusted life-years (QALYs) than BCT only
over 6 months (mean difference 0.0477 (0.0257,0.0699).
Conclusion: USGI triamcinolone/lidocaine plus BCT leads to greater
improvements in pain and function over 6 months in adults with hip OA
than BCT alone, and was highly cost-effective. There was no
significant difference in hip pain intensity between the groups receiving
USGI triamcinolone/lidocaine and USGI lidocaine only, raising the
possibility of a degree of placebo effect.
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Background: With an aging population, the burden of musculoskeletal
aging in joints, bones and muscles carries with it significant morbidity.
Osteoarthritis (OA) is the most common joint condition, and can be
defined clinically or radiologically. Musculoskeletal aging in bone and
muscle can be assessed through change in body composition, grip
strength and physical performance. The aim of this study was to
investigate whether a diagnosis of radiological knee OA impacted
involution in muscle or bone in the midlife in a group of community-
dwelling older adults in the UK.
Methods: Our study comprised 220 members of the Hertfordshire
Cohort Study (118 males and 102 females), a group of community
dwelling older adults in the United Kingdom. Knee radiographs were
performed at baseline (1999-2003), with osteoarthritis defined as a
Kellgren and Lawrence score 2. At baseline and follow-up (2017)
questionnaires assessed physical activity and lifestyle factors; JAMAR
dynamometry was performed to assess grip strength; 8 foot walk test
was performed to assess gait speed and DXA was performed to
assess bone mineral density at the hips and body composition. Linear
regression was performed to analyse associations in males and
females, before and after adjustment for follow-up time, lifestyle
factors (including smoking, alcohol consumption, social class, calcium
intake and physical activity), anthropometric measures (BMI) and HRT
use and age at menopause in women. The development of hand
osteoarthritis was adjusted for grip strength outcomes.
Results: The mean age of participants at baseline was 65.0 years.
Median follow-up was 16.7 years (range 15.0-18.4 years). Knee
osteoarthritis was present in 75 (34%) participants. Radiographic knee
osteoarthritis status at baseline was significantly associated with grip
strength (b¼-3.2kg, -5.3 to -1.1, p<0.01) at follow-up in females but
not in males (b¼-2.9, -5.8 to 0.1, p¼0.06). No significant associations
between radiographic osteoarthritis status at baseline and other
measures of sarcopenia (gait speed or lean mass) or bone mineral
density were found in either sex.
Conclusion: Our findings demonstrate that the presence of knee
osteoarthritis in midlife can have a substantial bearing on grip strength
in women over 15 years later independent of the presence of hand
osteoarthritis. Grip strength has been shown to correlate closely with
lower limb strength and so the demonstrated association between grip
strength and knee osteoarthritis is representative of a global weakness
resulting from the disease. Reduction in grip strength has been
associated with an increased risk of morbidity including falls and
fractures. Thus, in order to countermand this association, it may be
that concerted interventions (including physical therapy, strengthening
and surgical intervention) should be recommended for those with knee
osteoarthritis at this stage in the lifecourse. Of course, these findings
require replication and validation in other cohorts.
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